As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly...
Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a...
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...
Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable...
Danish pharma Novo Nordisk has agreed to acquire US clinical-stage biopharma Forma Therapeutics in a deal worth $1.1 billion that will expand its blood disorders...
Danish companies Novozymes and Novo Nordisk Pharmatech are teaming up to develop technical enzymes to support biopharma processing. The companies aim to develop high...
Danish pharma Novo Nordisk has agreed to buy Dicerna Pharmaceuticals, offering $3.3 billion for the US biopharma and its ribonucleic acid interference (RNAi) platform.
